New hope for kids with tough cancers: first test of donor cell therapy
NCT ID NCT05400603
Summary
This is a first-in-human safety study testing a new type of donor immune cell therapy for children whose neuroblastoma or osteosarcoma has come back or hasn't responded to standard treatments. The main goal is to find the safest dose of these cells when given alongside a combination of four other cancer drugs. Researchers will enroll up to 24 children to see if this approach is tolerable and shows any early signs of helping control these aggressive cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.